Loading...

MALLINCKRODT PLC Company Mergers 8-K Filing

MLLN

MALLINCKRODT PLC

()

2026 8-K

Financial Results Update

CEO Employment Agreement

Stock Incentive Plan

Spin-off Details

Financial Results Report

Fiscal Year Change

Financial Statement Disclosure

Spin-off Announcement

Mallinckrodt Acquisition

Preferred Shares Issued

Shareholder Meeting Results

Financial Disclosure

Management Change

Management Change

Stock Incentive Plan

Asset Acquisitions

Asset Acquisitions

Merger of Equals

Merger of Equals

Merger of Equals

Merger of Equals

Compensatory Arrangements o...

Financial Statements

Transaction Agreement

Merger Agreement

Merger Agreement

Financial Results

External Links:

On March 31, 2026, Keenova Therapeutics plc announced unaudited financial results for Q4 2025, forecasting 2026 net sales of $1.94B to $2.00B and Adjusted EBITDA of $730M to $760M, while pursuing divestiture of its Percocet business which is expected to generate $65M in net sales.

AI Assistant

MALLINCKRODT PLC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.